

PROVINCIAL FUNDING SUMMARY

Enzalutamide (Xtandi) for Metastatic Castrate Resistant Prostate Cancer, first-line

pERC Recommendation: Recommends with condition on the cost-effectiveness being improved to an acceptable level

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: July 8, 2015

This information is current as of March 29, 2016.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Oct 1, 2015	Patients with metastatic castration resistant prostate cancer who are either chemotherapy naïve or have received prior chemotherapy containing Docetaxel*. ECOG performance status 0-2. Life expectancy greater than 3 months. A BCCA "Compassionate Access Program" (CAP) request must be approved prior to treatment. * Patients are eligible to receive abiraterone (UGUPABI) OR enzalutamide (UGUPENZ) OR cabazitaxel (UGUPCABA) but not sequential use of these agents.
AB	Funded	Dec 18, 2015	For the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy who have not received prior chemotherapy or if patients are unable to tolerate ongoing abiraterone in this pre-docetaxel setting.
SK	Funded	July 29, 2015	Treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy who have not received prior chemotherapy.
MB	Funded	Jan 18, 2016	For the treatment of histologically confirmed metastatic castrate-resistant prostate cancer with disease progression after prior androgen deprivation therapy and no prior chemotherapy.

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
ON	Funded	Aug 31, 2015	<p>For the treatment of metastatic castrate-resistant prostate cancer (mCRPC) in patients who meet the following criteria:</p> <ul style="list-style-type: none"> · The patient is asymptomatic or mildly symptomatic after failure of androgen deprivation therapy; AND · The patient has an ECOG* ≤ 1; AND · The patient must not meet any of the exclusion criteria stated below. <p>*ECOG = European Cooperative Oncology Group Status Renewals will be considered in patients with evidence of not having had disease progression while on Xtandi therapy.</p> <p>Exclusion Criteria: Funding for Xtandi will NOT be approved in patients who meet any ONE (or more) of the following exclusion criteria:</p> <ul style="list-style-type: none"> · The patient has risk factors for seizures; · The patient is using Xtandi in combination with Zytiga for metastatic castration-resistant prostate cancer; · The patient has used and experienced disease progression on Zytiga*; OR · The patient has received prior chemotherapy for mCRPC. <p>*Requests for Xtandi in patients who initiated Zytiga therapy and who have not had disease progression while on Zytiga will be considered on a case-by-case basis.</p>
NS	Funded	Nov 2, 2015	<p>As a single agent treatment for asymptomatic or mildly symptomatic metastatic CRPC patients after failure of androgen deprivation therapy (including an LHRH agonist/antagonist or orchiectomy) who have not received prior chemotherapy for metastatic CRPC, ECOG PS 0-1 and no risk for seizures. Enzalutamide would be an alternative to abiraterone and not sequential therapy in this asymptomatic or mildly symptomatic patient population.</p>
NB	Funded	Oct 14, 2015	<p>For treatment of patients with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and have not received prior chemotherapy, Clinical Notes: · Patient must have no risk factors for seizures · When used as first line treatment, patient must have an ECOG performance status < 1 · Will not be reimbursed in combination with abiraterone</p>

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
NL	Funded	Oct 1, 2015	For the treatment of patients with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) who have evidence of disease progression following androgen deprivation therapy (ADT), who have not received prior chemotherapy for mCRPC and who have an ECOG performance status of 0 or 1, and no risk factor for seizures.
PEI	Funded	Feb 22, 2016	For treatment of patients with metastatic castration resistant prostate cancer who: Are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy with an ECOG performance status ≤ 1 and have not received prior chemotherapy and would be an alternative to abiraterone for patients and not sequential therapy in this asymptomatic or mildly symptomatic patient population. Notes: Enzalutamide will not be reimbursed in combination with abiraterone.